Here is information about recent NASPCC webinars. Use the links below to view the recorded webinar and handouts:
“Theranostics in Prostate Cancer*”
With Dr. Michael Morris, Section Head of Prostate Cancer, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center in New York
Recorded: January 11, 2021
* Theranostics describes the combination of using one radioactive drug to diagnose and a second radioactive drug to deliver therapy to treat the main tumor and any metastases
About the Presenter
Dr. Michael Morris is a prostate cancer specialist, clinical investigator, and the Section Head of Prostate Cancer of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center. He earned his medical degree from the Mount Sinai School of Medicine in New York, and performed his internship and residency in Internal Medicine at Columbia Presbyterian Medical Center. He then completed his medical oncology fellowship at Memorial Sloan- Kettering Cancer Center, where he was the Chief Fellow as well.
Dr. Morris has led numerous clinical trials, but he has a particular research focus on targeted therapy for prostate cancer, especially those that bridge the fields of Medical Oncology and Nuclear Medicine. In the field of therapeutics, he has focused on radio immunotherapy and other radio-conjugates, bone directed therapy, and other targeted therapies. In the field of diagnostics, he has a keen research interest in developing novel imaging technologies for metastatic prostate cancer and in developing novel imaging biomarkers. He has been a co-developer of the Prostate Cancer Working Group 2 and 3 Consensus Criteria, and novel prostate-specific imaging technologies such as FDHT PET and PSMA-directed PET imaging.
In addition, he is the Medical Director of the Department of Prostate Cancer Clinical Consortium and chairs the GU Committee of the Alliance for Oncology Trials in Oncology (formerly CALGB).
Resources
- Access to the January 11, 2021 recording.
- Powerpoint from the January 11, 2021 webinar - plugin required
“Incontinence and Sexual Side Effects of Prostate Cancer Treatment”
With William Brant, MD, FACS, FECSM, Urologist & Men’s Sexual Health Physician in Salt Lake City, Utah
Recorded: Tuesday, December 8, 2020
About the Presenter
Dr. Willam Brant attended Dartmouth College and the University of Washington, and obtained his MD at the University of California, San Diego. He completed residencies in Surgery and Urology at the University of Colorado Health Sciences Center and a fellowship in sexual medicine and surgery at UCSF. Dr. Brant’s practice is dedicated to Men’s Health, with a particular focus on sexual and erectile medicine; male urinary incontinence; penile reconstructive surgery; and prosthetic surgery. His current practice is divided between Summit Urology/Granger Medical Clinic and the Salt Lake City Veterans Affairs Medical Center.
Dr. Brant is a member of the AUA, the Sexual Medicine Society, and the Society of Urologic Prosthetic Surgeons, among others. He has authored over 100 works, including various chapters in 6 textbooks in Urology.
Resources
- Access to the December 8, 2020 recording.
- Powerpoint from the December 8, 2020 webinar - plugin required
“The PROCEED Registry and Disparities Work in Metastatic Prostate Cancer”
With Dr. Andrew Armstrong, Professor of Medicine, Surgery, Pharmacology and Cancer Biology and Director of Research, the Duke Cancer Institute Center for Prostate and Urologic Cancers at Duke University.
Recorded: Wednesday, November 4, 2020
About the Presenter
Dr. Andrew Armstrong is a tenured Professor of Medicine, Surgery, Pharmacology and Cancer Biology and Director of Research for the Duke Cancer Institute’s Center for Prostate and Urologic Cancer. He is a medical oncologist and internationally recognized expert in experimental therapeutics and biomarker development in genitourinary cancers, particularly in prostate cancer. He trained at Duke as a biomedical engineer, received his medical degree at the University of Virginia, medicine residency training at the University of Pennsylvania, fellowship and public health clinical investigation training at Johns Hopkins and the Bloomberg School of Public Health, and joined Duke’s faculty in 2006.
Dr. Armstrong has developed a number of experimental agents in prostate and renal cell cancer, including completed or ongoing trials of AR inhibitors, immunotherapies, mTOR/PI3K inhibitors, and anti-angiogenic agents, and is heavily involved in the leadership of multiple ongoing phase 1-4 treatment and biomarker trials in men with advanced prostate cancer including serving as correlative science chair within the NCI ALLIANCE Cooperative Group in the GU Committee. He has authored over 170 peer reviewed publications as well as numerous chapters, reviews, and abstracts. He leads a team of over 50 research nurses, coordinators, data managers, regulatory specialists, scientists, and investigators dedicated to discovery science in GU cancers in the laboratory and treatment science in the clinic. As an R01 funded clinical-translational investigator, he has mentored over a dozen medical oncology fellows and junior faculty, and many residents and students both in the clinical, for clinical trials, and for laboratory training.
Resources
Sponsor
NASPCC is receiving support for this webinar from Dendreon:
“Immunotherapy and PARP Inhibition”
With Dr. Judd Moul, Professor, Duke University Medical Center.
Recorded: October 5, 2020
About the Presenter
Judd W Moul, MD, FACS is the James H Semans MD Professor of Surgery at Duke University. In 2004, after completing a 26-year U.S. Army career and retiring as full Colonel in the Medical Corps, Moul became Chief of the Division of Urologic Surgery at Duke. Serving as Chief until 2011, he established the Duke Prostate Center (DPC) and directed the development of a DPC Outcomes database that contained the records of over 10,000 prostate cancer patients.
Dr. Moul serves on the editorial boards of American Journal of Men’s Health, Urology and Prostate Cancer and Prostatic Diseases. He serves on the Executive Committee for the American Joint Commission for Cancer (AJCC). Dr. Moul has published over 600 medical and scientific manuscripts and book chapters and has lectured at national and international meetings. He has been a visiting professor and invited guest lecturer at universities and national symposia, in addition to appearances on ABC, NBC, CNN, PBS, and other media as a prostate cancer authority. Honors and awards received have included the American Medical Association’s Young Physicians Section Community Service Award, the Sir Henry Welcome Research Medal and Prize from the Association of Military Surgeons of the United States, the Gold Cystoscope Award by the American Urological Association, the Baron Dominique Jean Larrey Military Surgeon Award for Excellence, the Order of Military Medical Merit from the Surgeon General of the US Army, and the Castle Connolly National Physician of the Year award in 2009. *Dr. Judd Moul is not receiving any compensation for this presentation*
Resources
- Access the Oct. 5, 2020 archive recording
- PowerPoint from Oct. 5, 2020 presentation - plugin required
Sponsor
NASPCC is receiving support for this Webinar from Dendron:
“PSMA Imaging in Prostate Cancer: New Developments”
With Dr. Michael Morris, Clinical Director, Memorial Sloan-Kettering Cancer Center in New York
Recorded: October 1, 2020
About the Presenter
Dr. Michael Morris is prostate cancer specialist, clinical investigator, and the Section Head of Prostate Cancer of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center. He earned his medical degree from the Mount Sinai School of Medicine in New York, and performed his internship and residency in Internal Medicine at Columbia Presbyterian Medical Center. He then completed his medical oncology fellowship at Memorial Sloan-Kettering Cancer Center, where he was the Chief Fellow as well.
Dr. Morris has led numerous clinical trials, but he has a particular research focus on targeted therapy for prostate cancer, especially those that bridge the fields of Medical Oncology and Nuclear Medicine. In the field of therapeutics, he has focused on radio immunotherapy and other radio-conjugates, bone directed therapy, and other targeted therapies. In the field of diagnostics, he has a keen research interest in developing novel imaging technologies for metastatic prostate cancer and in developing novel imaging biomarkers. He has been a co-developer of the Prostate Cancer Working Group 2 and 3 Consensus Criteria, and novel prostate-specific imaging technologies such as FDHT PET and PSMA-directed PET imaging.
In addition, he is the Medical Director of the Department of Prostate Cancer Clinical Consortium, and chairs the GU Committee of the Alliance for Oncology Trials in Oncology (formerly CALGB).
Resources
- Access the Oct. 1, 2020 archive recording
- PowerPoint from Oct. 1, 2020 presentation - plugin required
Sponsor
This Webinar is sponsored by: Progenics Pharmaceuticals
“Exosome Testing and Liquid Biopsies – Risk Assessment for High-Grade Prostate Cancer: Home or Office Testing”
With Dr. Judd Moul, Professor, Duke University Medical Center.
Recorded: July 29, 2020
About the Presenter
Judd W Moul, MD, FACS is the James H Semans MD Professor of Surgery at Duke University. In 2004, after completing a 26-year U.S. Army career and retiring as full Colonel in the Medical Corps, Moul became Chief of the Division of Urologic Surgery at Duke. Serving as Chief until 2011, he established the Duke Prostate Center (DPC) and directed the development of a DPC Outcomes database that contained the records of over 10,000 prostate cancer patients.
Resources
- Link to the July 29, 2020 webinar archive recording
- PowerPoint deck from the July 29, 2020 presentation - requires plugin
- Prostate Cancer handout from Prostate Cancer and Prostatic Diseases - PDF
Sponsor
This Webinar is sponsored by: Exosome Diagnostics
Managing the Side Effects of Prostate Cancer and its Treatment: Emotional Distress, Intimacy Issues, Erectile Dysfunction and Incontinence
Recorded February 27, 2020
Sponsored by Boston Scientific.
Presenters
Dr. Krishnan Venkatesan, MD
Director of Urologic Reconstruction, Washington Hospital Center.
A native of Detroit, Dr. Krishnan completed his undergraduate studies at Columbia University in the City of New York before returning home for medical school at Wayne State University. He stayed on at Wayne State for his residency in Urology,which he completed in 2010. He then undertook a fellowship in Genitourinary Reconstruction at the Institute of Urology at University College London and went on to Pune, India to pursue further training in complex urethral reconstruction at the Kulkarni EndoSurgery Institute. Krishnan then moved to Washington, DC to become the Director of Urologic Reconstruction at MedStar Washington Hospital Center, a 900-bed urban tertiary care and trauma center. He is an Associate Professor in the Georgetown University Department of Urology and participates actively in resident training. Over his 7 years in Washington, he has developed the Reconstructive Unit into a referral center for complex genitourinary reconstruction and prosthetics throughout the Mid-Atlantic Region. He has had his work presented at the regional, national and international level, and has co-authored a number of publications in the urologic reconstruction subspecialty.
William Goeren, MSW, OSW-C, LCSW-R
Clinical Program Director,CancerCare, New York.
Bill Goren is the Director of Clinical Programs at CancerCare. Prior to his work at CancerCare, William was the Director of Mental Health for the AIDS Healthcare Foundation in Los Angeles, and, in 1994, opened the first Gilda’s Club in New York City. He is the co-author of the chapter “Unique Issues Confronting Gay, Lesbian, and Bisexual Individuals Diagnosed with Cancer” for the Oxford University Press Handbook of Oncology Social Work and the author of the chapter Social Work, HIV Disease, and Palliative Care” for the Oxford Textbook of Palliative Social Work.
Resources
- Link to the Feb. 27, 2020 webinar archive
- PowerPoint deck from the presentation - requires plugin
- Prostate Cancer handout from Boston Scientific - PDF
Webinar: Genetic Testing and Genetic Counseling in Prostate Cancer
Recorded May 09, 2018
Sponsored by Myriad Genetics
Dr. Leonard G. Gomella, Chair of the Urology Department at the Kimmel Cancer Center Network of Jefferson Medical College will be presenting on "Genetic Testing and Genetic Counseling in Prostate Cancer".
Resources
- Link to the May 9, 2018 webinar archive recording.
- Presentation slides - May 9, 2018 - 1st deck - PDF.
- Presentation slides - may 9, 2018 2nd deck - PDF.
Determine your hereditary cancer risk
Myriad Genetics is offering a free heredity cancer quiz. This brief questionnaire will help you determine whether you should be further evaluated for Hereditary Breast and Ovarian Cancer syndrome, Lynch syndrome, or other hereditary cancers:
Use this link to access the free heredity cancer quiz...
AR-V7 Splice Variant and Treatment Choices in Prostate Cancer
Recorded - April 3, 2018 with Ryan Dittamore and Deb Davison
Ryan Dittamore of Epic Sciences and Deb Davison from Genomic Health present on “AR-V7 Splice Variant and Treatment Choices in Prostate Cancer.”
This webinar was provided through a generous donation from Genomic Health.
Tissue Based Biomarkers for Localized Prostate Cancer
January 30, 2018 - with Dr. Ashley Ross, M.D., Ph.D.
- PowerPoint slides from the Jan 30, 2018 event in PDF format
- Link to recorded webinar (coming soon)
Dr. Ross' presentation was provided through a generous donation from Genomic Health.
rev: 10/08/2020
 Ashley Ross - January 2018 | [ ] | 4094 kB |
| Ryan Dittamore and Deb Davison - April 2018 | [ ] | 5500 kB |
| Article from Prostate Cancer and Prostatic Diseases | [ ] | 566 kB |